Abstract:It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.Supporting tables; 1H NMR, and 13C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)Predicted binding mode of 6a in the ATP pocket of JAK2; surface representation of 6a in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)Predicted binding mode of 15d in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)Predicted binding mode of 16b in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)Predicted binding mode of 6a in the active site of HDAC6; surface representation of 6a in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)Predicted binding mode of 15d in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)Predicted binding mode of 16b in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies

Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model

Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer

Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response

Immune modulation underpins the anti-cancer activity of HDAC inhibitors

Discovery of Epigenetic Modulators Targeting Hdacs and Ezh2 Simultaneously for the Treatment of Hematological Malignancies

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

Novel Hybrid Molecule Overcomes the Limited Response of Solid Tumours to HDAC Inhibitors Via Suppressing JAK1-STAT3-BCL2 Signalling

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Dasatinib Synergises with Irinotecan to Suppress Hepatocellular Carcinoma Via Inhibiting the Protein Synthesis of Plk1

Identification of Candidate Predictive and Surrogate Molecular Markers for Dasatinib in Prostate Cancer: Rationale for Patient Selection and Efficacy Monitoring

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II

Systematic identification of genomic markers of drug sensitivity in cancer cells

Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Responsive Signatures Established by Pharmaco-Transcriptomic Correlation Analysis Identifies Subsets for PARP-targeted Therapy and Reveals Potential Synergistic Interactors